Catalyst Wire Dossier Catalyst Wire Dossier

Obrixtamig

BI 764532 · Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Obrixtamig, covering 2026-04-02 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy [Phase 3]

See pricing